Should Scientific Research in the Lead-up 
I. Abstract
In Canada, the availability of generic drugs owes its his article is an analysis of case law pertaining to pedigree to compulsory licensing. 1 As part of its per- Property (TRIPS), Canada repealed its compulsory The NOC Regulations belong to a class of legal instrulicensing regime for pharmaceuticals in favour of ments referred to as ''linkage regulations'' that tie patent ''linkage regulations'' referred to as the Patented protection for marketed pharmaceuticals to the CanaMedicines (Notice of Compliance) NOC Regulations dian drug approval process. Therefore, the NOC Regula-(the ''NOC Regulations''). 2 The substance and procedure tions control entry of generic drugs into the market and of the NOC Regulations were modelled on analogous access by the public to affordable medication. The issue legislation in the United States. 3 So-called linkage regulaof testing arises out of the complex and inverse relationtions tie patent protection for marketed pharmaceuticals ship between inventiveness and obviousness in patent to the drug approval process, and thus control both entry law such that the lower the threshold for inventive ingeof generic drugs into the Canadian market and access by nuity in the patentability analysis, the higher the Canadians to affordable medication. Under the Canathreshold for parties attacking patents on grounds of dian linkage regulation regime, the typical route for a obviousness. The present analysis demonstrates there is generic pharmaceutical company to obtain market substantial uncertainty in Canadian jurisprudence over access for its product is to attack the relevant brandwhat constitutes the accepted test for obviousness. Some name pharmaceutical company's patents for being either cases stand for the proposition that no testing whatsoinvalid (on the grounds of, for example, obviousness, ever is allowed, others for the opposite proposition that anticipation, double patenting, and claims broader than some testing is allowed, while still others purport to disclosure) or to claim that its product will not infringe follow the former while actually applying the latter. Hislisted patents. Given that a substantial percentage of the torical cases supporting the ''no testing'' line of cases cases litigated under linkage regulations in Canada and were analysed and found to offer no strong legal precethe United States involve allegations of invalidity based dent for this approach. It is suggested that courts adopt a on obviousness, 4 the test for obviousness determines, in ''purposive test'' for obviousness based on Canadian law part, the availability of generic medications in North requiring patents to be construed purposively rather America. than literally, federal policy underlying the NOC Regulations requiring application of regulations in a manner When assessing the issue of obviousness, courts are that is fair and balanced to all parties, and Supreme charged with addressing whether an invention is renCourt of Canada jurisprudence requiring fair, unequivdered obvious in light of previous disclosures. 5 This analocal, and predictable application of laws. The proposed ysis involves a determination of whether the impugned test would be consistent with appellate court jurispruinvention represents an ''inventive step'' over previously dence in other jurisdictions with analogous patent legisdisclosed inventions. 6 One problem that frequently lation and policy.
comes up in the obviousness analysis is whether or not †© R. A. Bouchard 1 experimental research or testing conducted by the patreasons. First, because courts are releasing inconsistent entee in order to arrive at the invention constitutes this opinions on the issue (no testing versus some testing) kind of inventive step. Under Canadian law, courts are and the opinions themselves are internally inconsistent obliged to carry out the analysis from the perspective of a (courts say they are applying one standard but actually person skilled in the relevant art casting their mind back apply another). Secondly, because judicial reasoning on to the claim date. The specific question addressed in this the inventive capacity of persons skilled in the art contrapaper is: Should scientific research and testing convenes normative practices in the pharmaceutical ducted during the lead-up to invention automatically industry, which in turn unfairly biases the legal test for vitiate a finding of obviousness for a party attacking the obviousness in favour of patentees. Part IV contains recpatent on grounds of validity under the NOC Regulaommendations for law reform. A purposive approach to tions?
obviousness is proposed which focuses not on binary notions of testing/no testing, but rather on the essence The question is not an easy one. The concepts of and context of inventive activity leading up to invention obviousness and inventiveness in patent law are inversely from the vantage point of the skilled technician. The related and linked through the inventive ingenuity of decision of Justice Gibson in Bristol Myers Squibb v. relevant persons skilled in the art. A lower standard for Novopharm 8 is used as an example of how the central inventiveness in the patentability analysis equates to a elements of a purposive construction might be applied higher standard for obviousness for parties attacking the to the test for obviousness. Finally, Part V discusses applipatent on grounds of obviousness. Not surprisingly, cation of the purposive approach to pharmaceutical litibrand-name and generic pharmaceutical companies seek gation conducted outside the umbrella of the NOC Regdiffering standards for inventiveness and obviousness.
ulations. Brand-name firms desire a relatively stringent standard for inventiveness such that any research or testing undertaken to arrive at an invention will result in a patent monopoly. Under this strict standard, a generic company
III. Statutory Requirement and faces the fact that if evidence of testing is adduced then

Classical Test
its attack on patent validity must fail. By contrast, generic y 1996 amendment to the Patent Act 9 (the ''Act''), a firms seek a more flexible standard for inventiveness, Bstatutory requirement for obviousness came into with the result that some testing is allowed without autoforce for patent applications after October 1, 1989. 10 Secmatically vitiating a finding of obviousness. As will be tion 28.3 of the Act does not however provide a statutory discussed in detail below, it is perhaps not surprising that definition of obviousness beyond reference to relevant courts have had difficulty in grappling with this complex persons skilled in the art. As noted by the courts 11 and issue.
practitioners, 12 the common law test prior to codificaThe present analysis is split up into five parts. In Part tion has continued to be applied. I, the case law on obviousness is canvassed with the The leading common law test for obviousness in objective of determining whether or not there is in fact a Canada was articulated by Justice Hugessen in Beloit v. coherent the NOC Regulations. While many judges apply the stone for obviousness is the technician skilled in the art but leading decision in Beloit v. Valmet 7 to the effect that no having no scintilla of inventiveness or imagination; a partesting is allowed, others judges have seen fit to allow agon of deduction and dexterity, wholly devoid of intuition; a triumph of the left hemisphere over the right. The quessome testing provided it is non-inventive in nature, while the effects of this on potential litigants. It is concluded that the constitutional requirement for fairness, predictThus, for Justice Hugessen, and the considerable ability, and certainty in law applies to the test for obvicorpus of patent law relating to the obviousness test ousness, and that this requirement is breached for two relying on his judgment, 14 there are only two perspec-tives from which to view a patent: that of an inventor, conducted in the laboratory or within the confines of a and that of a person skilled in the art. One is completely library or presumably even on the Internet. This passage inventive while the other is not inventive at all. The has a substantial history in the judicial analysis of obviobviousness test is to be gauged only by the latter. As we ousness in Canada. 18 The second line of cases involve the shall see below however, the lack of convergence notion that if more than a ''mere scintilla'' of inventivebetween the judicial construction of persons skilled in ness is exercised on the road to invention, 19 then the the art and actual skilled technicians in the global pharinvention cannot be obvious. Both lines of cases are maceutical industry has led to considerable judicial summarized in Table 1 infra. Applied together, they manipulation of the case law in order to get around the result in a high barrier for parties alleging invalidity restrictive language of Beloit. based on obviousness, leading Justice Hugessen in Beloit to say ''it is a very difficult test to satisfy' '. 20 The high watermark in pharmaceutical or chemical
IV. Analysis
cases for the stringent standard is Justice Lederman's trial decision in Bayer v. Apotex, 21 In Bayer, the obviousness Part I: NOC Case Law analysis focused on three interrelated issues: the ''no testing'' approach to obviousness and the related ''worth review of pharmaceutical case law demonstrates a try'' obviousness formulation, and whether a person
Athere is substantial confusion in Canadian courts skilled in the art ''would have'' or ''could have'' arrived at regarding the amount of scientific research during the the impugned invention. The case involved a compullead-up to invention allowed to be contemplated in the sory license for nifedipine, a dihydropyridine Ca 2+ obviousness analysis by persons skilled in the art. On one channel blocker used in the treatment of various cardiohand, many judges have articulated a stringent standard vascular disorders. The issue of validity revolved around of ''no experimentation or serious thought'' (''no testing'' nifedipine's poor activity as a solid dosage form, poor for shorthand) while others have taken a more flexible solubility in water as a liquid form, and significant light approach, allowing testing that is ''due'', ''mechanical'', or sensitivity; all of which led to difficulties in arriving at a ''routine'' without vitiating the obviousness attack.
dosage form with good bioavailability and rapid onset of Adding to the confusion is the fact that still other courts action. have articulated one standard while silently applying the other. Thus it is hardly surprising that one recent deciApotex argued that the invention set out in Canasion involved the application of a much less stringent dian Patent No. 981, 582 (the '582 patent) was obvious test under anticipation than under obviousness, which is given the disclosure in a South African patent applicatraditionally a much harder ground of attack to make tion that nifedipine could be used to treat acute angina out in patent litigation. 15 Part I of the analysis is therefore when administered either intravenously or orally and broken up into three sections: (a) decisions that apply the that it worked like nitrates, e.g., nitroglycerin. Apotex stringent standard, (b) decisions applying the more flexcontended it was obvious to put nifedipine in liquid ible standard, and (c) decisions that claim to follow the form and then encase the solution in a soft gelatin capformer approach but apply the latter.
sule in order to deliver it perlingually, as had been previously done for nitroglycerin. Given the relevant prior art (a) Stringent Standard and common knowledge attributed to persons skilled in the art of pharmaceutical science, problems overcome by As noted above, the test articulated in Beloit does the '582 patent, such as light sensitivity and insolubility not refer explicitly to scientific research or testing, in the could easily be overcome through routine trial and error lead-up to invention or otherwise. The origin of the testing. Apotex argued that such testing would be roustringent standard can be traced back to two lines of tine workshop activity and therefore would involve no historical cases. 16 The first comprises legal commentary inventive ingenuity. 22 by Professor Harold Fox to the effect that no testing whatsoever can be carried out in the context of the Apotex made out its case based on the ground that obviousness analysis:
testing conducted in the work-up phase to the invention
In order that a thing shall be ''obvious'' it must be by persons skilled in the art constituted non-inventive or something that would directly occur to someone who was obvious testing. However, Justice Lederman rejected this searching for some-thing novel, a new manufacture, or approach, citing the Federal Court's decision in Cabot whatever it might be, without the necessity of his having to Corp. v. 318062 Ont. 23 (citing Fox) to the effect that no do any experimenting or serious thought, or research, whether the research be in the laboratory or amongst literatesting could be undertaken in the context of obvi- ture. 17 ousness. This was true even under conditions where the In this formulation, the standard for scientific impugned testing was both logical and reasonable in research or testing that vitiates the obviousness attack is light of the prior art. 24 A second ground offered by Jusvery stringent. Not only is no experimenting, serious tice Lederman was based on his interpretation of the thought or research whatsoever allowed under the obviinventive capacity of relevant persons skilled in the art ousness test, but this includes all research, whether it is articulated in Beloit. In particular he relied on the pro-position that persons skilled in the art are to be conby the inventor crossed the line from mere workshop strued as having ''no scintilla'' of inventiveness, imaginaactivity into the realm of inventive ingenuity based on tion, or intuition. 25 Such a person would, quite evidence before the court as interpreted by one skilled in obviously, undertake no testing in order to arrive at an the appropriate art. 35 The approach taken in Bayer invention. The notion that even a mere scintilla of invenunduly benefits patentees because it minimizes the legal tion is sufficient to justify patentability in the context of burden of having to adduce evidence proving that a validity attack has a long history in Canada 26 and the testing undertaken by them to arrive at the invention United Kingdom. 27 would have been inventive in nature. Rather, under the Bayer test, it need only be proved that some testing was Rather than addressing the issue of testing conducted in the lead-up to the invention, following directly, 28 Justice Lederman re-phrased Apotex's arguwhich a finding of obviousness is automatically vitiated. ment as ''worth a try'' rather than the routine experimenConsequently, rejection of routine testing in favour of tation or workshop improvement approach advocated the no testing approach, substitution of the former with by Apotex. 29 As noted above, this formulation is a logical the worth a try approach, and reliance by the court on extension of the ''no testing'' approach; by definition the the distinction between could and would all marginalize worth a try approach would allow some testing. Justice persons skilled in the art in the obviousness analysis. Lederman also expressed an abundance of caution Table 1 (Appendix 1) below summarizes decisions relating to the issue of hindsight. 30 However, the worth a to date where testing was not allowed in the obviousness try approach to obviousness differs significantly from analysis. As in Tables 2-3 infra, the tabulated decisions one addressing the issue of routine experimentation.
are split up into NOC and non-NOC cases. In Table 1 , While it minimizes hindsight error it does so at the cost the cases are further split into the two lines of cases of allowing a person skilled in the art to make an underpinning the ''no testing'' approach: cases traceable informed decision as to whether or not an invention is back to Fox's explicit injunction against testing, and cases obvious based on the evidence before the court as of the traceable to the injunction against the exercise of more claim date. As such, it minimizes the role of persons than a ''mere scintilla'' of inventiveness. skilled in the art in the obviousness determination, which is then left in the hands of the presiding judge. As discussed more fully below, this contradicts the require-(b) Flexible Standard ments of section 28.3 of the Act, which stipulates that Critical to understanding why and how a skilled persons skilled in the art are to provide the lens through formulator would (or could) contemplate testing a comwhich the judiciary must gaze when addressing the issue pound for its properties is the nature of the tacit and of obviousness.
focal codified knowledge 36 possessed by the ordinary A second important aspect of the decision in Bayer person skilled in the art in the pharmaceutical industry. was the court's distinction between whether a person As noted by Justice Snider in a recent case involving skilled in the art ''would have'' or ''could have'' arrived at crystalline forms of azithromycin, pharmaceutical comthe invention based on prior art. As with the worth a try panies litigating under the NOC Regulations are sophisapproach, favouring the term ''would'' over ''could'' can ticated multinational firms, capable of rapidly and effibe seen as an extension of the no testing approach, as ciently conducting all necessary research relating to the clearly one of these terms encompasses some testing optimal design, medical chemistry, formulation, dosage while the other does not. The Federal Court of Appeal's forms, manufacturing, and storage of pharmaceutical ''cling free'' case 31 was cited as authority for the could products. 37 Indeed, once a pharmaceutical compound versus would distinction. However, this distinction was has been synthesized, it routinely undergoes considernever made by Justice Urie in Beecham. 32 Indeed, not able testing relating to each of these broad issues. 38 As only was it not made, but it can be argued that Beecham pointed out by Wolfe and colleagues in the context of is cited primarily in the case law for the proposition that innovation clusters, 39 the life sciences industry is heavily to be obvious a person skilled in the art must come dependent on both synthetic and analytical knowledge directly and without difficulty to the solution taught by bases. 40 Unfortunately, while the identity and inventive the patent. The distinction by Justice Lederman between capacity of relevant persons skilled in the art have been whether a person skilled in the art would versus could understood within the pharmaceutical industry for have arrived at the invention has been applied in many many years, very few judges have made an attempt to subsequent cases. 33 understand in detail the nature of the ''persons'', ''skills'', or ''art'' in the context of cases under the NOC RegulaIn rejecting any allowances for testing, the court in tions. Indeed it can be argued that much of the confueffect marginalized the skilled technician in the obvision in Canadian courts over the issue of testing can be ousness analysis. As noted by Justice Martland writing in traced back to a fundamental misreading of this issue. 41 dissent in Farbwerke v. Halocarbon, 34 use of the term ''would'' in this context amounts to a rejection of the Based on the above discussion, the relationship more flexible Cripps Question, where emphasis is placed between inventiveness, obviousness and the inventive on investigation into whether or not activity engaged in capacity of persons skilled in the art is crucial to a proper understanding of the issue at hand, as it informs the ''routine'', ''workshop'', or ''mechanical'' testing. An normative context in which ''routine'' scientific research understanding of these terms is therefore central to a occurs in the pharmaceutical sector. One of the few pragmatic test for obviousness that is faithful to the tacit decisions in recent years where the issue was addressed and focal knowledge bases and normative practices directly is Justice Reed's decision in Apotex v. Hoffmann- within the global pharmaceutical industry. For example, La Roche. 42 The case offers a good example of the fact in an early case involving a method for coating moulded that a substantial amount of testing can be routinely masonry, the Exchequer Court of Canada held that obviundertaken by a skilled formulator (or team of skilled ousness turns on the nature of the skills of the person formulators) as part of the normal drug formulation skilled in the art as they are applied to the specific task at exercise:
hand. In particular, an invention is patentable only where it is or not ''beyond the expected skill of the Once a compound such as trimethoprim has been synthesized there are various tests through which it must go calling'' or ''beyond the skill of the routineer''. 46 properties of the compound. The compound once created is There is no inventiveness in following an obvious and then sent to a research facility for testing both in vitro (in well-charted route using known techniques and processes glass) and in vivo (in life). In vitro testing is that which involving known compositions unless the inventor occurs in a test tube or more precisely in small glass saucer encounters difficulties that could not have been reasonably shaped dishes (petrie dishes). a man who is going to try to achieve success and not one looking for difficulties or seeking failure'', stated:
Testing was not without difficulty. Initially the batches of trimethoprim were of uneven purity. The most signifiHaving determined that a wet formulation of paroxecant difficulty however arose from a report received in Septine tablets gives rise to a ''pink hue problem'', a problem of tember 1960 that chronic toxicity studies carried out in significant enough magnitude to cause a skilled person to dogs had found severe leucopenia, that is a severe drop in seek out at least a partial solution to the problem, I am the white blood cell count. But, those results could not be satisfied that a logical first step for a person skilled in the art reproduced. By December 1961 clinical trials had comwould be to turn to the alternative formulation methods menced at Hammersmith Hospital in London and Dr.
disclosed by the '060 Patent and to determine whether each Bushby was attempting to interest other medical centres in or any of those alternative formulation methods would doing likewise. 43 solve, or at least partially solve, the problem. Such an enquiry would, I am satisfied, involve no inventive step or
As to whether such significant and ''difficult'' testing skill. It would simply involve application of the invention should vitiate the obviousness attack, Justice Reed held taught by the '060 Patent. 49 that evidence before the court indicated that testing of Thus, routine investigation of the matter at hand sulphamethoxazole with trimethoprim was nothing includes logical, rational, or incremental steps toward other than an ''entirely obvious routine, indeed, mechansolving the problem at issue. As exemplified by the reaical step to take''. 44 Sensibly, the amount of allowable soning of Justice Reed in the trimethoprim decision, the testing is not without limitation. As noted by Justice question to be answered is whether or not such steps are Reed in a different decision, routine testing can only inventive, e.g., nonobvious. render a claim invalid where it involves no inventive step. 45 Central to the concept of allowable testing articuSimilarly, in Janssen-Ortho v. Novopharm, 50 a case lated by Justice Reed in both of these cases is that testing involving the l-isomer of the antibiotic levofloxacin, the outside the bounds of obviousness involves an inventive court allowed non-inventive testing relating to a number step, whereas that inside the obviousness fence does not.
of characteristics of the compound at issue, including the Although grounded in Supreme Court of Canada and (i) solubility, (ii) toxicity, and (iii) degree of antimicrobial other appellate jurisprudence (cf . Table 2 ), this distincactivity of levofloxacin compared to the previously distion has been largely ignored in cases where the more closed racemic mixture of the same drug ofloxacin. Jusstringent standard is applied.
tice Mosley held that, given the previous patent on the Many decisions under the NOC Regulations racemic mixture, it would have been obvious to a person allowing some form of testing employ terms such as skilled in the art to conduct testing on the solubility, toxicity, and the degree of antimicrobial activity of the lthreshold for testing was ''crystal clear and without the isomer and that such testing was non-inventive. At need for experimenting or serious thought''. 56 However, various points in the judgment, the court described the court went on to find that no inventive ingenuity or testing on these variables as mechanical, routine, ''undue experimentation'' was exercised in prescribing involving simple analytical procedures that were uncomsertraline for panic disorder or obsessive compulsive displicated and generally accepted, and that revealed no order: new uses, surprising results, or properties. 51 Therefore, compositions unless unexpected difficulties were encountered. 57 Together, the decisions stand for the proposition that acceptable testing is testing that falls short of inventive-A similar result was obtained in the second of two ness and which allows the skilled technician to come cases involving the proton pump inhibitor omeprazole, directly and without difficulty to the invention at issue. AB Hassle v. Genpharm. 58 While Justice Layden-SteThese cases are clearly at odds with those summarized in venson stated clearly that for an invention to be obvious Table 1 .
it must occur directly to the skilled person ''without serious thought, research or experiment'', 59 the test she (c) Cases That Cite Stringent Standard But Apply actually applied was that in the AZT trial decision to the Flexible Standard effect that there is no inventiveness in following an obvious and well-charted route using known techniques Confusing the case law even further is a third line of and processes involving known compositions unless the cases in which judges grappling with the complex eviinventor encounters difficulties that could not have been dence before them cite the stringent standard, yet, with reasonably expected by a person versed in the art, or varying degrees of silence, go on to apply the more flexovercome by the application of ordinary skill. Justice ible test. For example, in the Apotex v. Wellcome AZT Layden-Stevenson found that nothing in Apotex's evitrial decision, Justice Wetston specifically cited Bayer to dence indicated that testing conducted by Hassle was the effect that for an invention to be obvious, no routine and, therefore, the invention was not obvious. 60 thought, research or experiment could be undertaken on Thus, while the court was willing to apply a more liberal the road to discovery. 52 However, the standard actually test than did Justice Campbell in the first omeprazole applied by the court was that of no ''undue experimentadecision, 61 evidence adduced by Apotex was, as in that tion'': case, simply insufficient to demonstrate obviousness.
There is no inventiveness in following an obvious and well-charted route using known techniques and processes Another case on point is Novartis v. Apotex. 62 involving known compositions unless the inventor Novartis involved formulations of cyclosporin purported encounters difficulties that could not be reasonably expected by a person versed in the art or overcome by the to solve the problem of poor bioavailability through the application of ordinary skill. 53 use of concentrated microemulsions. The '150 patent held by Novartis was invalid on grounds of anticipation, Consequently, the court accepted that some testing obviousness, and because the claims were deemed could be allowed in the obviousness analysis without broader than the disclosure. The court dealt extensively vitiating a finding of obviousness. As noted earlier, Justice with the issue of the skilled formulator and what would Wetston's reasoning on the issue parallels that of the or would not be properly construed as part of the Exchequer Court in Burns & Russell in this regard. 54 normal formulation exercise. Based on the facts before Nevertheless, the court held that the proffered evidence the court there were as many as four separate steps to go was overly speculative and would have entailed undue from the prior art to the invention. The main issue was experimentation in order to arrive at the impugned phrased as follows: invention. 55 Even so, Justice Wetston clearly left open the possibility that testing would not per se obviate a finding . . . Apotex alleges that the technician skilled in the art with of obviousness. Thus, it is not surprising that many of the the teachings of the two '667 and '307 patents would understand that to improve the stability and the bioavailability cases in Tables 2 and 3 refer to this decision. produced by the delivery system of these patents, a
Similarly, in a case involving the selective serotonin microemulsion process would be needed so that a formulare-uptake inhibitor (SSRI) sertraline for panic and obsestion of a high surface area of oil in contact with water which sive-compulsive disorder, the court stipulated that the permits the cyclosporin to partition into the water and be absorbed across intestinal mucosa into the bloodstream, court, the court held that testing engaged in by Novartis would result.
was not inventive and therefore that the invention was obvious. 66 The key question is whether the formulator skilled in the art would be aware that the smaller the droplets' size, A similar result was obtained in two decisions the higher the surface area of contact between oil and water enhance, and thus, the better the drug blood levels that involving the ␤ adrenoceptor antagonist carvedilol for result. 63 congestive heart failure 67 and the antibiotic azithromycin. 68 In the latter decision, Justice Mosley stated that Laying the groundwork for his analysis, Justice Blais no ''experimentation or research'' is permissible under cited with approval the ''worth a try'' approach articuthe obviousness test. 69 However, later in his reasons he lated in Bayer and Fox's statement that to be obvious an actually found that the testing by Pfizer in order to prove invention must be arrived at without any experimenting, that its dosage form of azithromycin did not demonserious thought or research. However, Justice Blais did strate a food effect was routine and did not constitute not hold that testing engaged in by Novartis was per se undue experimentation. 70 Consequently, the invention inventive. Rather, he addressed several complex and was obvious. Similarly, in Glaxosmithkline, Justice Noël lengthy aspects of the evidence that shed important light cited Bayer and Fox to the effect that no research whaton what a person skilled in the art would have known soever could be undertaken in the obviousness test, 71 but and grappled with, presumably in the absence of invenactually found that testing undertaken by GSK constitive ingenuity. 64 The not-insignificant exercise the skilled tuted non-inventive testing, with the result that the formulator faced in attempting to solve the problem invention was obvious. 72 before the court involved several overlapping considerations, including that compositions of cyclosporin within A summary of cases where judges cite the stringent the claimed patents would be in the form of a prestandard as authority, but then go on to apply the more concentrated microemulsion, that such emulsions flexible standard is provided in Table 3 in the Appendix increase the rate of mass transfer of cyclosporin from the below. It is clear that a significant number of cases fall oil to aqueous phase, that such an increase would be into this category. inversely related to emulsion droplet size, and in turn result in increased bioavailability of the drug in a patient's body:
(d) Summary
Apotex suggests that in view of the teachings of the '667 and '307 patents and the literature available, a skilled formuAs can be seen from the data in Tables 1-3 and lator would understand that well formulated compositions discussion thereof in the text, there are three divergent within the scope of the '667 and '307 patents would be a microemulsion preconcentrate as claimed in claim 1 of the lines of case law pertaining to obviousness in Canada '150 patent and it follows that emulsion and microemulsion under the NOC Regulations: (i) those that adopt a strinsystems were developed as a means to increase the mass gent ''no-testing'' approach; (ii) those that adopt a flexible transfer rates of the drug to the aqueous phase. It was also approach; and (iii) those that appear to adopt the former well known that the rates of the mass transfer of the drug to approach but actually apply the latter. The cases underthe aqueous phase would increase as the size of the oil droplets decreased, e.g., the smaller the droplets' size, the pinning the no testing approach can themselves be split higher the surface area of contact between oil and water into two groups. The first can be traced back to Professor enhance, and thus, the better the drug blood levels. The real Fox's legal commentary on this topic, while the second question is whether every formulator skilled in the art can be traced back to the intersection of obviousness and should know that the higher [the] surface area of the disinventiveness and the injunction against the exercise of persed phase (oil in water), that is a small particle size emulsion, the greater the absorption/bioavailability. even a mere scintilla of inventive ingenuity by persons skilled in the art. The remainder of this article will conApotex suggests that the emulsion and the microemulcentrate on the former line of cases; the second is dealt sion processes were commonly known in the industry and with in forthcoming work. 73 Together, they are often that the formulators skilled in the art were aware of these referred to in NOC jurisprudence as the ''accepted processes at the time of the patent. 65 approach'' to obviousness. This seems to conflict howFrom this passage it can be gleaned that based on ever with the data in Tables 2 and 3 , which indicate the known art regarding (a) microemulsion systems and (b) presence of two other distinct (and growing) contrary the relationship between the size of emulsion droplets to lines of jurisprudence. The only conclusion one can mass transfer rates, the skilled formulator would have draw from this analysis is that while Fox, Beloit and known that: (i) reducing droplet size would increase Bayer are routinely cited as leading authority on the droplet surface area, and (ii) that this increase in surface issue of testing there is no single authoritative line of area would result in an increase in bioavailability due to jurisprudence indicating whether or not scientific testing (iii) increased absorption, and that all of the above might in the lead-up period to an invention should vitiate a (iv) solve known problems with cyclosporin bioavaifinding of obviousness. by the means, described by Haas. This was, I think, someIn order that a thing shall be ''obvious'' it must be thing novel and useful, particularly because of its adaptasomething that would directly occur to someone who was bility for use in bakeries as already mentioned, and I do not searching for something novel, a new manufacture, or think there is any fair ground upon which it should be whatever it might be, without the necessity of his having to denied the merit of a patentable invention, unless, as I have do any experimenting or serious thought, or research, already stated, anticipation of it has been definitely estabwhether the research be in the laboratory or amongst literalished. There would not seem to be any room for saying that ture. 75 Haas was something obvious. In order that a thing shall be ''obvious,'' it must be something that would directly occur for both otherwise differ significantly. 76 Indeed, obviThe statement by Justice Maclean to the effect of ousness and anticipation constitute separate and distinct ''no experimenting or research'' thus sits somewhat legal requirements under Canadian, American, and uncomfortably as a bald statement with no apparent British patent law. However, Fox's position on anticipaprecedent in Canadian law. tion parallels his injunction against experimenting in the obviousness analysis: inventive ingenuity in an invention Neither of the two remaining decisions by Justice exists where experiments were necessary to show Maclean 82 entails a review of, or even mentions, previous whether or not it could be usefully carried out. 77 In other case law pertaining to obviousness. Tellingly, these cases words, experimentation trumps a finding of anticipation.
are never cited in later decisions supporting the stringent Consequently, the test for obviousness can be conflated standard: only the passage by Professor Fox is quoted, into that for anticipation. As noted by Justice Hughes in minus any reference to the cases cited by him. Confusing a recent NOC case involving levofloxacin, the lack of elements of Justice Maclean's reasoning in Short Milling inventiveness attributed to persons skilled in the art in have not escaped judicial notice, as revealed by the folcases employing the stringent standard comes ''perilously lowing passage from the decision of Justice Collier of the close'' to that for anticipation, with the result that obviFederal Court in Xerox v. Around 1912 the Watson Smith resin was investigated by Notwithstanding the very ingenious and exhaustive chemists in the employ of General Electric Company in the argument of counsel for the appellant, we would hardly United States, their names being, among others, Callahan, think, however, he would ask this Court to give a sacroArsem, Dawson, Howell and Friedburg. These chemists sanct meaning to the use of the word ''obvious'' for the were trying to make out of this hard glassy substance of purpose of discriminating between the category of Watson Smith, a sample whereof was filed as exhibit 24, improvements which ought to be regarded as being something soluble in available solvents and thus industrially properly inventions in the legal sense and the category of useful, something they could spread on a surface as a those not so regarded.
coating. 89 It has long been laid down in our courts that, in
The evidence adduced clearly demonstrates that order validly to support a patent, it was, of course, necessary that the art, or the improvement thereon, should be General Electric was in the habit of conducting largenew, that it must be useful and that it must not have scale routine research on a stable of compounds, and been anticipated by prior knowledge or prior user by that it was deemed acceptable by the court at the time others within the meaning of sec. 7 of the Patent Act, in Fox was writing his book not just for one person skilled force at the time of the issuance of the patent in suit; but that something additional was also required. It was essenin the art, but rather an entire team of skilled chemists tial that there should be invention and that one did not employed by this large sophisticated industrial company, hold a valid subject-matter of a patent unless he showed to undertake significant experimental research, and that and theoretical research conducted by the General Elec- R.P.C. 518 H.L.) , ''a degree of ingenuity . . . which must tric research group, Justice Angers found that the patent have been the result of thought and experiment' '. 88 was obvious in light of the prior art. The result, and the It is clear from the passage at the bottom of the means to get there, parallels that in the trimethoprim, preceding paragraph that at no point in his decision did levofloxacin, cyclosporin and sertraline cases discussed Justice Rinfret hold that ''any experimenting or research, supra, where evidence of substantial testing was adduced whether the research be in the laboratory or amongst without automatically vitiating a finding of obviousness. . Tables 2 and 3) . Recall in that case that Justice ever, the Supreme Court of Canada has said that one of Gibson found with reference to the existing case law that the primary functions of law is to give the public fair routine testing is within the skill of persons skilled in the notice of the legal nature and consequences of its conart and thus does not support a patent monopoly. This duct with reasonable certainty through the fair applicareasoning was adopted in the leading case of Apotex v. tion of laws by courts. 95 As stated by Justice Gonthier in Wellcome when the court held ''there is no inventive-R. v. Nova Scotia Pharmaceutical Society, this notice ness in following an obvious and well-charted route function is ''broadly linked with the corpus of principles using known techniques and processes involving known of government known as the 'Rule of Law', which lies at compositions unless the inventor encounters difficulties the core of our political and constitutional tradition' '. 96 that could not have been reasonably expected by a The requirement for fairness, predictability, and cerperson versed in the art or overcome by the application tainty in law applies in two important ways to the issue of ordinary skill''. 91 at hand. First, the case law review clearly illustrates that Another early case noteworthy for having dealt there is a significant lack of certainty and predictability directly with the issue of testing is the Supreme Court of with regard to the standard for testing within the obviCanada decision in Lightning Fastener v. Colonial Fastousness rubric. This refers to the fact that courts are both ener. 92 Justice Rinfret stated that inventions brought releasing inconsistent opinions on the issue (no testing about through the exercise of mechanical skill do not versus some testing) and opinions which are themselves involve an exercise of inventive ingenuity, and that it ''is internally inconsistent (judges say they are applying one not the object of the Patent Act to dignify by the name standard but actually apply another). Secondly, courts are of invention every slight advance in the domain of adopting reasoning that flies in the face of normative mechanism''. A similar distinction was made by the practices within the pharmaceutical industry and Exchequer Court in Pope Appliance v. Spanish River. 93 applying this reasoning in a manner that inherently and Thus, while the need for caution in distinguishing thus unfairly biases the legal test for obviousness against between inventive and non-inventive experimenting, second persons under the NOC Regulations. thought, and research had been sounded by the courts, 94 In one of its leading patent cases, 97 the Supreme there can be little question that by 1969 there was a well Court of Canada stipulated that the provisions of the Act developed line of cases in Canada distinguishing the type and interpretation thereof by the judiciary should be fair of routine or workshop testing advocated by Apotex in and predictable. Extending the principles enunciated in Bayer, from inventive testing done on the road to a Nova Scotia Pharmaceutical, Justice Binnie noted that patentable invention.
there is a certain minimal standard of predictability that must attach to patent law jurisprudence, beyond which (b) Summary significant and improper economic harm can result to The historical survey undertaken above casts doubt patent litigants. The court further held that it is within on the legal foundations of the stringent standard for the bounds of proper patent policy to maintain this minobviousness. In the absence of strong supporting jurisimal level of certainty and predictability and to keep it prudence, Professor Fox's commentary in and of itself from slipping below that threshold: stands as poor precedent for the proposition that any
The scope of patent protection must not only be fair, it scientific testing at all in the lead-up to invention should must be reasonably predictable. A patent is, after all, a public instrument issued under statutory authority which vitiate a finding of obviousness. Together with the two may result in severe financial consequences for its infringeother lines of jurisprudence relating to this issue ment. The scope of its prohibition should be made clear so reviewed in Part I and summarized in Tables 2 and 3 it is that members of the public may know where they can go reasonable to conclude there is an absence of an unewith impunity. As was said in another public law connection by Gonthier J. in R. v The patent owner, competitors, potential infringers and turn will broaden their risk zone. Third, the consequence the public generally are thus entitled to clear and definite to the public of not having a test for obviousness that is rules as to the extent of the monopoly conferred. This in fair and predictable is that a significant percentage of the turn requires that the subjective or discretionary element of claims interpretation (e.g., the elusive quest for ''the spirit of population will be at risk of losing access to affordable the invention'') be kept to the minimum, consistent with medications. It is known, for example, that the longer a giving ''the inventor protection for that which he has actufirm is able to maintain a dominant market position, ally in good faith invented'' (Western Electric Co. v. Baldwin particularly one relating to patented pharmaceuticals, the International Radio of Canada, [1934] S.C.R. 570, at p. 574).
longer it will continue to maintain monopolistic pricing Predictability is achieved by tying the patentee to its claims; fairness is achieved by interpreting those claims in an schemes. 100 Finally, a high threshold test creates a lack of informed and purposive way. 98 incentive for innovation in the pharmaceutical sector, While the court was concerned with the scope of which in turn yields fewer and less innovative products the claims at suit, the requirement for clear and definite for consumers and for potential inventors to build on. rules can be legitimately extended from claim scope to Indeed, Varma and Abraham have described the obvithat of obviousness. Both analyses go to the heart of ousness test as the gate by which patent law minimizes patent validity; one through the proper scope of the inefficient transfers of wealth under conditions where a patent monopoly and the other through the existence of patentee obtains a right to exclude others from making the monopoly itself. If a court finds that a given claim or or using their invention, yet does not add to the store of set of claims are broader than the disclosure, then those public knowledge when a patent is granted on obvious claims are deemed to be invalid. The same is true for subject matter. 101 The relevance of this to Canadian drug obviousness, which can result in complete invalidation consumers is evident in the Supreme Court of Canada's of a patent rather than invalidation on a claim by claim recent statement that it ''is entirely understandable'' that basis.
brand-name pharmaceutical firms would avail themselves of provisions in the NOC Regulations allowing It could also be argued that maintaining the evergreening by ''adding bells and whistles to a piothreshold for allowable testing at the current stringent neering product'' after the original patent has expired. 102 standard results in significant ''chilling'' of competition The economic rationale for spending $10 million to to the benefit of patentees. This follows the resulting make $500 million in profit instead of spending $500 ambiguity and uncertainty faced by potential litigants. In million to make $2 billion is relatively straightforward. Free World Trust, the Supreme Court of Canada held
The result of this situation is that brand-name drug comthat patent policy, not unlike competition law and panies are strongly incented to leverage the regulations policy, should encourage and not discourage economic to produce products that clearly do not benefit the activity. In particular, the court noted that an improperly public. expanded patent scope results in chilling of competition to the detriment of both competitors and the public:
(
b) Implications for the Issue of Fairness
The patent system is designed to advance research and development and to encourage broader economic activity.
In addition to issues of certainty and predictability, afoul of the fairness principal, particularly where the Competition is ''chilled''. The patent owner is getting more stated purpose and intent of the relevant enabling legislaof a monopoly than the public bargained for. There is a high tion is to balance the interests of all relevant parties and economic cost attached to uncertainty and it is the proper policy of patent law to keep it to a minimum. 99 ensure national public health interests are respected by making affordable medication available. This concern is In the pharmaceutical industry, the consequences of particularly relevant in light of the fact that expenditures this type of chilling are significant: First, as noted in Free by Canadians on prescription drugs have risen by several World Trust, patentees accrue more of a monopoly than hundred per cent in the last two decades, 103 with no that bargained for by the public. This skews the balance slowing in the growth rate expected in the future. of patent law against potential competitors, concentrating wealth in the hands of fewer firms, and main-
The purpose and intent of legislation can be taining monopolistic pricing from the perspective of gleaned by government policy documents, including testing or research whatsoever without obviating a must find for brand-name firms. The person skilled in However, as can be gleaned from the second parathe art, who under the provisions of section 28.3 of the graph supra, in addition to safeguarding the interests of Act, is to supply the lens through which the judiciary is brand-name pharmaceutical firms, the government also to gaze when assessing obviousness, is obliged by law to intended to protect the rights of generic firms under the operate at the highest level of scientific and technical new regulations. The balancing function was been consophistication, yet possess not even a scintilla of creativity firmed more explicitly in the December 2004 RIAS:
or inventiveness when contemplating testing in the obvi- realized was established in 1993, with the enactment of Bill C-91, the Patent Act Amendment Act, 1992, S. C. 1993, c. 2. 108 (c) Summary This balancing of interests was recently acknowledged by the Supreme Court of Canada in its Biolyse In summary, a requirement for fairness, predictdecision, in which Justice Bastarache stated that amendability, and certainty in application of the test for obviments to the NOC Regulations were intended to ''conousness can be located in the Rule of Law, Supreme firm the balance between providing effective enforceCourt patent jurisprudence and statements by legislators ment of patent right, while ensuring that second and regarding the intent and purpose of the NOC Regulasubsequent entry manufacturers' drugs can enter the tions. This requirement is breached in two ways by the market as soon as it is determined that they are not stringent test for obviousness. First, because it yields a covered by a patent, or, where they are covered by a situation where there is a substantial lack of certainty patent, immediately after the patent expiry' '. 109 Similar and predictability as to the correct standard for testing within the obviousness rubric. And second, because a particularly important consideration in jurisdictions courts have adopted reasoning in the obviousness analsuch as Canada, where regulatory approval of ysis that inherently and thus unfairly biases the legal test pharmaceuticals is controlled by linkage regulations, against generic firms under the NOC Regulations. which in turn allows for line extension patents that can be continually evergreened. 121 Part IV: Suggestion for an Unequivocal,
In addition, the Supreme Court of Canada noted
Predictable, and Fair Test that courts must take a purposive approach not only to infringement but also to validity, in order to avoid construing claims differently for purposes of infringement (a) Purposive Construction of Obviousness and validity. 122 Similar reasoning applies to differences As reviewed above, there is a small but growing between claim construction and obviousness. Finally, as number of judges who have moved away from Beloit with claim construction, taking a purposive approach to and Bayer to allow research or testing in NOC cases obviousness would satisfy the interpretive objective in without obviating a finding of obviousness. Judicial reapatent law of being ''reasonable and fair to both the soning in these cases typically entails articulation of patentee and the public''. 123 As well, it would respect the ''due'', ''rational'', ''incremental'', ''routine'', ''mechanical'', public notice function of law. 124 or ''workshop'' testing. In these decisions a finding for or Particularly important to the issue at hand is that a against generic firms was based on the evidence before purposive construction is said to achieve ''flexibility and the court, expert opinion, and an appreciation of contexfairness'' in law by focusing on the essence or so-called tual practices of persons skilled in the art in the pharma-''pith and marrow'' of an invention. 125 This broad focus ceutical industry. 114 As such, the tests applied by these can be contrasted to the narrow focus on literal notions courts was objective yet flexible.
of testing versus no testing in the stringent approach to A useful starting point for discussion of an unequivobviousness (or the would versus could distinction). A ocal, predictable, and fair test is by way of analogy to the purposive approach would involve an enquiry into the issue of claim construction, which according to the nature of the research or testing leading up to the invenSupreme Court of Canada must be made in a pragmatic tion, the focal point being a determination of whether or and informed way. 115 In Whirlpool v. Camco, for not the testing was inventive. The term ''purposive'' need example, the court, following the Federal Court of not be used; any term connoting a functional and pragAppeal in Eli Lilly v. O'Hara 116 and the House of Lords matic approach aimed at assessing the essence of invenin Catnic v. Hill & Smith, 117 held that patent claims tive activity would suffice. No matter what the termishould be construed ''purposively'', whereby emphasis is nology used, the purposive approach comports well to placed on locating the essence of an invention with the the implicit reasoning employed by many of the judges aid of persons skilled in the art (rather than interpreting in decisions where testing was allowed, including those the words of the inventor literally). Viewing the patent where the judiciary claimed to follow the stringent stanthrough a skilled interpreter minimizes, in the words of dard but actually applied the more flexible one. Lord Diplock, reliance on the type of literal and ''meticulous verbal analysis in which lawyers are too often A recent case under the NOC Regulations can be tempted by their training to indulge' '. 118 used to illustrate how the central elements of a purposive While the courts in Whirlpool and Catnic were construction might be applied to obviousness. BMS v. concerned with claim construction rather than Novopharm 126 involved gatifloxacin, a quinolonecarboxvalidity, 119 an emphasis on the ''essential nature'' of the ylic acid antibiotic. Evidence indicated that research into invention and how it came to be is a constant feature in quinalones had been intense and extensive among both analyses. In the case of claim construction it is highly qualified persons skilled in the art for 10 years distinguishing between essential and non-essential eleprior to the claim date. 127 Justice Gibson approved of ments of the claim, whereas in the obviousness analysis it statements by Novopharm's lead expert that the science is the determination of whether the act of arriving at an involved in producing the invention (medicinal cheminvention crosses the line between inventive and nonistry) was more predictable than experts for BMS had inventive activity. Moreover, both assessments are to be claimed. 128 Regarding the issue of testing, the court made contextually, 120 with the help of persons skilled in noted the prohibition in Beloit against any experiment, the art. The issue of context is no less important to the thought, or research involving more than a ''mere scinissue of obviousness, as no invention least of all those in tilla'' of inventiveness. However, given the evidence the multinational pharmaceutical industry arises in before him as to the inventive capacity of persons skilled vacuo. All advances, be they large or small, evolve based in the art of pharmaceutical science, he rejected the test on previous discoveries. To say that obviousness can only in Beloit in favour of the more flexible approach, casting be found in the absence of experimentation, thought, or the definition of persons skilled in the art ''well above research is to deny the manner in which discoveries are the concept of an individual having no scintilla of invenmade and reduced to practice, and essentially conflates tiveness or imagination' '. 129 Referring to the decisions in the test for obviousness into that for anticipation. This is Apotex v. Wellcome 130 (AZT), Pfizer v. Apotex 131 (sert-raline) and Janssen-Ortho v. Novopharm 132 (levofloxin practice but that this need not be equivalent to legally acin) discussed supra, he allowed routine testing that fell obvious, 137 even though this scenario runs against the below the threshold of undue or inventive testing. This grain of analyzing a patented invention contextually 138 included testing that produces surprising or unexpected through the eyes of a person skilled in the art, 139 with a results. 133 As in Justice Reed's articulation of allowable mind willing to understand 140 all that is necessary in testing in the Apotex v. Hoffmann LaRoche 134 order to successfully solve the problem before them 141 trimethoprim case, the court noted that what constitutes enabled by all relevant prior art and best-practices in the ''routine testing'' in the context of obviousness must be industry at the time of the claim date. 142 dependant upon evidence adduced before the court. The Canadian approach can be contrasted with that Based on such evidence Justice Gibson held that the in the United Kingdom not only with regard to obvipatent was not obvious, finding specifically that the chief ousness but also anticipation, the latter of which is tradiexpert for Novopharm admitted on cross-examination tionally a harder ground of invalidity to make out. For that the starting point in his analysis was not the prior example, in the classic case of Van Der Lely v. art, but rather the invention in question. This led him to Bramford, 143 the House of Lords held that ordinary conclude that Novopharm's expert was engaged in a methods of trial and error testing can anticipate an classic hindsight analysis. 135 invention, provided they do not involve an inventive While the claims were ultimately held to be valid, step. Included in the scope of allowable testing are ordiJustice Gibson's analysis is consistent with the purposive nary methods of trial and error that involve no inventive approach outlined above. It was grounded in context at step and are generally necessary in applying any disthe time of the claim date and evidence adduced before covery to produce a practical result. 144 This contrasts the court. His decision turned on evidence pertaining to sharply with the Canadian position on anticipation the degree of activity in the field at the time of invention, articulated by Fox and applied in Beloit and later cases. the somewhat predictable nature of the science and
The leading United Kingdom case on testing in the techniques involved in producing the invention, the fact context of obviousness is Lord Mustill's Court of Appeal that some degree of testing is routinely employed in the decision in Genentech. 145 The case stands for the propharmaceutical industry, and the fact that persons skilled position that an invention is obvious when analyzed in the art are in reality not completely devoid of invencontextually if it can be determined through well known tive ingenuity. The latter two observations go to the testing techniques involving trial and error. The court heart of purposive construction as they are directed spemade a distinction between a notational skilled technicifically to whether research conducted by BMS was cian attempting to put an invention into practice and inventive or not. The fact that evidence showed such persons skilled in the art operating in a ''discovery testing was inventive does not detract from taking an capacity'' in a field where intelligence and problemapproach that seeks to understand the pith and marrow solving abilities are both valued and normative. The of the matter. Rather, it highlights the value of taking a court found it appropriate in cases involving complex contextual and evidence-based approach to obviousness biomedical inventions to assume people who are skilled rather than focusing on binary notions of testing/no in the art posses a substantial degree of problem-solving testing or would/could. The test is flexible rather than ability. Indeed, the court held that ''but for'' the creative stringent, and thus is fair to both litigants. skills of relevant persons skilled in the art they would not A purposive approach would also reconcile imporhave been included on the discovery team in the first tant differences in obviousness jurisprudence in Canada place. It is these skilled technicians who make up the and the United Kingdom that persist in spite of the population of persons skilled in the art to which the increasingly global nature of drug development and court must look when assessing obviousness. The reaintellectual property rights attaching to pharmaceutical soning of Lord Mustill on this point parallels that of inventions. As noted by Justice Lederman in Bayer, a Justice Gibson in BMS v. Novopharm, Apotex v. Hoffsignificant discrepancy exists in the inventive capacity of mann-LaRoche and the AZT trial decision, 146 and is preEnglish and Canadian persons skilled in the art such that sent in varying degrees in all of the cases enumerated in ''making inquiries or testing, seems to be something Table 2 and many of those in Table 3 . Another point of outside the ken of the notional Canadian skilled techniconvergence was the court's holding that the skills of the cian' '. 136 Justice Lederman went on to say while it may person skilled in the art must be construed contextually, have been logical to a person skilled in the art to underbased on evidence brought before the court. 147 take testing, that it was not open to the mythical skilled technician who can not have an inquiring mind. Rather, Finally, Lord Mustill laid the burden for weighing the law in Canada stands for the proposition that a considerations of obviousness squarely on the judiciary skilled technician is expected to spontaneously exclaim notwithstanding the caution to avoid hindsight in the ''I already know the answer and it is obvious''. Reasoning obviousness analysis. 148 In looking to the essence of the of this kind led Justice Blanchard in the recent Pfizer v. issue, courts in the United Kingdom are therefore Novopharm azithromycin ''food effects'' case to say that charged with the burden of determining whether the it can be scientifically obvious to arrive at an invention problem faced by the inventor ''could have been over-come by pertinacity, sound technique, or trial and error, The primary ground of appeal in Teleflex is that the with no more, or whether there would have been Federal Circuit has retreated significantly from the test required a spark of imagination'' beyond that properly laid down by the Supreme Court in its John Deere deciattributable to persons skilled in the art. It is left to the sion: judge to form a mental picture of the art and skilled While the ultimate question of patent validity is one of practitioner, and see how the latter measures up against law, the condition set forth in the Patent Act of 1952, 35 the problem which he or she is assumed to be U.S.C.S. § 103, which is but one of three conditions, each of which must be satisfied, lends itself to several basic factual attempting to solve. Given the pragmatic and functional inquiries: (1) the scope and content of the prior art are to be approach taken by him it is not surprising that determined; (2) differences between the prior art and the numerous Canadian tribunals, including the Patent claims at issue are to be ascertained, and (3) significantly from that in Canada, however, as courts in pertains. 157 the United States have tended to focus on differences Thus, as in Canadian patent law, the lens through between the structure and function of biomedical invenwhich the judiciary must gaze when determining tions, 153 ignoring strong evidence of functional obviwhether the invention was a patentable advance over the ousness in favour of analyzing the prior art in light of the relevant prior art was that of the person having ordinary level of uncertainty relating to the structural aspect of skill in the art, typically referred to in American legal therapeutic molecules. Canadian courts, by contrast, commentary as the PHOSITA. However, counsel for tend to take the evidence as they find it in cases under KSR and numerous amicus curiae, including the United the NOC Regulations, focusing on structure or function States Solicitor General and Twenty Four Intellectual as alleged by the attacking party in its Notice of AllegaLaw Professors (''Law Professors''), claim that the Federal tion.
Circuit has retreated from the John Deere factors, The role of persons skilled in the art in the obvireplacing them instead with a more stringent and inflexousness analysis has recently garnered considerable ible test requiring that a specific ''suggestion, teaching or attention in the United States. In May 2006 the United motivation'' to combine the relevant prior art teachings States Supreme Court solicited the opinion of the Solicin the manner claimed must be demonstrated to support itor General on whether it should hear KSR Internaa finding of obviousness. 158 This is analogous to Canational Co. v. Teleflex Inc. et al., 154 a case involving a dian courts adopting the more stringent test in the concombination patent directed to an adjustable gas pedal text of testing. As noted by one prominent patent for use in throttle control and an electronic control to scholar, 159 this has resulted in the gradual marginalizacommunicate adjustments from the adjustable gas pedal tion of persons skilled in the art in obviousness cases to the engine. KSR, a Canadian corporation, was granted generally, leaving room for considerable judicial review summary judgment against Teleflex in its infringement of lower court findings of fact based on a less deferential suit. The lower court decision was overturned on appeal standard of review. 160 to the Federal Circuit, leading to the petition by KSR. The case is highly pertinent to the present analysis as it The requirement to find in evidence such a specific involves the first substantial determination of the nature piece of prior art contravenes the Supreme Court's direcof a court's proper reliance on persons skilled in the art tion in John Deere toward applying a ''functional when deciding the issue of obviousness by the United approach'' articulated by the court earlier in Hotchkiss v. States Supreme Court since Graham v. John Deere. 155 Greenwood. 161 As noted by Justice Clark in John Deere, The court granted certiorari June 26, 2006 and heard the Hotchkiss formulation, ''lies not in any label, but in oral argument in late November 2006. A decision is its functional approach to questions of patentability' '. 162 expected in spring 2007.
In practice, Hotchkiss has required a comparison between the subject matter of the patent, or patent applivery difficult to satisfy' '. 170 It will be recalled that the cation, and the background skill of the calling. It has same concern was articulated by Justice Lederman in been from this comparison that patentability was in each Bayer as grounds for the no testing/worth a try approach case determined. As such, Hotchkiss and the pragmatic and the could /would distinction. As noted by the Solicapproach advocated in Part IV(a) supra share a basic itor General in its Teleflex brief, however, the strict test focus on the essence of an invention and the manner in articulated by the Federal Circuit constricts the test laid which it came to be. Another point of convergence is down by the Supreme Court in John Deere, which calls that the law is to be applied in a contextual manner on a for a flexible approach to obviousness. The Federal Circase-by-case basis. As is true of obvious determinations in cuit's test thus ''fails to account for the problem-solving Canada and the United Kingdom, 163 the United States abilities of persons of ordinary skill in the art'' and Supreme Court was mindful of the burden on the judi-''underestimates the capabilities of courts and patent ciary in rendering such determinations. However, as in examiners to 'resist the temptation' of hindsight and to the United Kingdom (but not Canada) the court was consider fairly the question of obviousness''. 171 As noted clear that such difficulties were not unlike those encoun- 165 that the Federal Circuit has the obviousness requirement asks of the court to determinimized the role of persons skilled in the art in the mine not what is already present in the prior art as of the obviousness analysis through the assumption, 166 paralclaim date, but rather whether a person skilled in the art leled in Canadian jurisprudence, that such persons are would deem the subject matter obvious in light of incapable of innovation and inventiveness, and by whatever prior art exists as of the claim date. 173 In conviewing obviousness as a question of law rather than one trast, the Federal Circuit's teaching-suggestion approach of fact. 167 As in Canadian cases where the judiciary recite requires the prior art to contain a particularized suggeslaw standing for the proposition that no testing is tion, teaching, or motivation to ground a finding of obviallowed but then find that the testing undertaken was in ousness: if no such specific suggestion, teaching, or motifact non-inventive, the Federal Circuit's jurisprudence on vation is put in evidence, then the invention must be obviousness has apparently created a similar type of deemed nonobvious This is clearly contrary to the double standard in the law by reciting the importance of United States Supreme Court's ruling in John Deere, persons skilled in the art to the obviousness analysis, leading the Solicitor General to recommend that KSR's then not depending on the skills or knowledge of such petition for writ of certiorari be granted. It is again remipersons when rendering decisions. 168 As claimed by the niscent of arguments made above in the context of ProSolicitor General and the Law Professors in their respecfessor Fox's legal commentary that the stringent standard tive briefs, this has resulted in a substantial lowering of for obviousness differs little from that for anticipation the bar for patentability, with a concomitant diminution under current Canadian law with regard to testing. in new discoveries and foreclosure of competitors' use of knowledge that would otherwise be in the public A final important issue arising out of Teleflex is the domain. 169 This is reminiscent of the discussion by the distinction between inventive and non-inventive (or Supreme Court of Canada in Free World Trust of the mechanical) testing. In its John Deere decision, the effect of an improperly defined patent scope to create an United States Supreme Court made comments undue ''commercial risk zone'' for competitors discussed regarding the role of persons skilled in the art relating to supra.
''routine testing'' that are pertinent to the analysis of The Federal Circuit has historically justified the relacases under the NOC Regulations. As noted supra, the tively inflexible teaching-suggestion approach based on court looked to its previous decision in Hotchkiss to the effort to avoid hindsight analysis, whereby persons interpret the proper scope of obviousness following its skilled in the art use the hindsight of prior art disclosed codification in the United States Patent Act in 1952. In after the priority date when analyzing the alleged invenHotchkiss, the court grappled with developing legal tion at the time of the claim date. Hindsight is a difficult means of facilitating the public disclosure of inventions problem to be sure, and was part of the reason for Justice that would not otherwise be disclosed or created but for Hugessen's claim in Beloit that the obviousness test ''is the inducement of the patent monopoly. ment. 182 Judicial review under the NOC Regulations is whether or not an invention is the work of a skillful considered to be an expedited proceeding and thus summechanic or an inventor, the court was clear that it was mary in nature. It does not entail a full determination of to be relevant persons skilled in the art. This determinavalidity or exploration of evidentiary matters that would tion is to be made on a case-by-case basis, giving rise to otherwise be before the court in an infringement prothe ''functional approach'' to patentability advocated by ceeding. 183 Therefore, formal conclusions on patent the Solicitor General in its amicus curiae brief. In John validity cannot be determined in litigation under the Deere, it was disputed by several parties that the require-NOC Regulations, notwithstanding that judicial reament for obviousness under § 103 was specifically soning and pronouncements on the issue of validity may inserted by amendment to the United States Patent Act parallel those in actions under sections 55 (infringement) in 1952 to overrule previous considerations of what conor 60 (impeachment) of the Act. The object of litigation stitutes ''the flash of inventive genius'', 177 and thus to under the NOC Regulations is solely to prohibit the specifically lower the bar for obviousness. 178 The court issuance of a NOC under the Food and Drug Regularejected this claim however, holding that the language in tions; 184 if a party desires a formal decision on the issue Cuno referring to inventive genius was nothing other of invalidity, they must avail themselves of remedies than ''rhetorical embellishment'' and did not create a under the Act. 185 Under this reasoning, applied recently differing standard. Rather, the court's previous decision in a post-NOC infringement action, 186 the law of obviin Cuno stood for the continuing proposition that nonousness would not be applicable to cases outside the obvious subject matter is subject matter that extends NOC Regulations. ''beyond the skill of the calling' '. 179 These are the exact words of Justice Gibson in Burns & Russell. This concept While operation of the NOC Regulations entails was also picked up on by the Solicitor General in its the odd result of a determination of validity which is Teleflex brief, as well as by the Law Professors in their only enforced within the ambit of the regulations themTeleflex brief. 180 The Law Professors extended this selves, it is clear from the common law and the addition notion specifically to litigation involving biomedical of section 28.3 to the Act in 1996 that determinations of technologies. In particular, they claimed that ''methodvalidity generally are to be made through the lens of ological advances provided an obvious path to new persons skilled in the art in light of all of the relevant results that should not themselves be patentable'', and prior art available as of the claim date. In addition, both that the Federal Circuit has sufficiently minimized the hurdles over which generic firms must jump (Fox's role of persons skilled in the art that it routinely applies injunction against testing per se and the ''no scintilla'' the obviousness test such that inventions are deemed to cases) in order to obtain a finding of invalidity, and their, be nonobvious ''even where the prior art demonstrates a application to pharmaceutical cases generally, are outside clear path for producing the invention' '. 181 the rubric of the NOC Regulations. Indeed, the judiciary have made no attempt to discriminate between the two streams of case law in rendering decisions under the (c) Summary NOC Regulations. Finally, jurisprudence and legal schol-A purposeful approach to obviousness is advocated arship from the United States and the United Kingdom for cases under the NOC Regulations. The proposed are outside the scope of the Regulations, yet apply to the approach focuses not on binary notions of testing/no issue at hand through the identity and inventive capacity of persons skilled in the art. Thus, there is no reason why Court of Canada that patent law should lend a degree of application of arguments made here regarding the role certainty and predictability to potential litigants and proof scientific testing in the lead-up period to an invention vide them with fair notice of when they can reasonably in the obviousness analysis can not be extended to litigaexpect to infringe the intellectual property rights of tion beyond the NOC Regulations.
others. Moreover, courts have adopted reasoning in the obviousness analysis that inherently, and thus unfairly, A note of caution in this regard is the recent biases the legal test in favour of patentees. The result is infringement opinion of Justice Hughes in Janssenthat generic pharmaceutical firms often lose cases Ortho v. Novopharm. 187 In this case it was held that even improperly on the issue of obviousness, in turn mainthough a prior decision under the NOC Regulations taining dominant market positions for brand-name firms found Novopharm's allegation that the impugned claims and monopolistic pricing on products that have often were invalid on grounds of obviousness was justified, the come off patent on the original new chemical entity. As same claims were held to be valid and infringed in the such, it was argued the current test creates an improperly context of subsequent infringement litigation. 188 Justice expanded ''risk zone'' for both the public and generic Hughes arrived at his decision based on his finding that firms. an action under the NOC Regulations does not constiIn addition, setting the threshold for scientific tute res judicata in subsequent infringement litigation. 189 testing to a de minimus level has the effect of placing an It remains to be seen whether this decision will withunfair evidentiary burden on generic pharmaceutical stand appellate scrutiny.
companies to prove invalidity within the context of a regulatory system that the Supreme Court of Canada has often referred to as ''Draconian' '. 191 This burden is onerous under conditions where the legal test departs
V. Summary and Conclusions
from the policy objective underpinning the NOC Regulations to balance the interests of brand-name and The purpose of this article was to analyze Canadian generic pharmaceutical companies. Indeed, both governcase law on obviousness pertaining to scientific research ment policy documents and Supreme Court of Canada and testing leading up to invention under the NOC jurisprudence clearly indicate concern for balancing the Regulations, and to highlight confusion in the courts and interests of both parties under the NOC Regulations. the manner in which the judiciary have attempted to
The same concerns have been expressed in the United grapple with the issue of testing in the obviousness analStates, which, ironically, given its strong innovation ysis. Some decisions were found to stand for the proposiagenda and pharmaceutical presence has undertaken sigtion that no experimenting or research whatsoever is nificant reforms to its linkage regime in order to facilitate allowed, while other cases stand for the opposite proposiprecisely such a balance. It is submitted that the lack of a tion that significant testing does not vitiate the obviclear, consistent, and appropriate test for obviousness ousness attack, while still others purport to use the represents a departure from maintaining an appropriate former standard while actually applying the latter. Thus, balance between the various private and public actors there is significant confusion in Canadian case law on involved in the commercialization, regulation, and conobviousness under the NOC Regulations.
sumption of pharmaceutical products in Canada. An analysis of the historical cases cited by Professor Finally, a suggestion was made toward a fair, uneFox in his injunction against experimentation, thought, quivocal, and predictable test which has its locus in or research in the lead-up to invention does not support Canadian law, federal policy underlying the NOC Reguthe ''no testing'' approach to obviousness. Indeed, anallations, and Supreme Court of Canada jurisprudence in ysis of this body of case law, along with decisions its leading patent decisions. The proposed ''purposive released contemporaneously but not cited by Fox, reveal construction'' of obviousness focuses contextually on that in fact extensive testing is routinely undertaken by whether or not experimentation or research conducted persons skilled in the art of pharmaceutical research, and in the lead-up to invention was inventive, rather than that courts had allowed such testing without vitiating a focusing on binary notions of testing/no testing or finding of obviousness. This discrepancy was demoncould/would. It provides a test that is fair and flexible for strated clearly by evidence adduced in an early Sherwinall parties to litigation, is wholly consistent with appellate Williams 190 chemical case, as well as in later cases jurisprudence, and which calls for law reform in other involving pharmaceuticals both outside of and under the jurisdictions with similar patent legislation and policy. umbrella of the NOC Regulations.
A lack of clear and definitive guidance by the courts has resulted in considerable arbitrariness, uncertainty, and a lack of predictability in the case law. It was argued that this runs afoul of the direction of the Supreme
